Sutro Biopharma, a biopharmaceutical company developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, today announced that it has entered into a collaboration ...
Tags: Bispecific Antibodies, Sutro's Cell-Free Protein Synthesis Technology
Sutro Biopharma has received $26m in a Series D financing, which will be used for the expansion of its proprietary immuno-oncology product pipeline. The company is currently using its cell-free protein synthesis technology to develop new ...
US-based biopharmaceutical company Immunomedics has announced the issuance of a US patent to its majority-owned subsidiary, IBC Pharmaceuticals, for ‘Novel Strategies for Improved Cancer Vaccines’. The new patent concerns ...
Immunomedics has developed two new classes of bispecific antibodies, DOCK-AND-LOCK (DNL) complexes using its patented platform technology that enables site-specific conjugation of two self-assembling modules. The bispecific antibodies ...